WO2012069902A1 - Kit cosmetique et utilisation pour ameliorer l'aspect de la peau - Google Patents
Kit cosmetique et utilisation pour ameliorer l'aspect de la peau Download PDFInfo
- Publication number
- WO2012069902A1 WO2012069902A1 PCT/IB2011/002746 IB2011002746W WO2012069902A1 WO 2012069902 A1 WO2012069902 A1 WO 2012069902A1 IB 2011002746 W IB2011002746 W IB 2011002746W WO 2012069902 A1 WO2012069902 A1 WO 2012069902A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- cosmetic
- kit according
- topical formulation
- mineral fillers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
Definitions
- the present invention relates to a cosmetic kit and its use to improve the appearance of the skin, in particular to prevent and / or fight against cellulite or orange peel and / or to refine the silhouette, to increase the elasticity skin, to intensify collagen synthesis, to increase blood microcirculation and to improve the thermoregulation of the skin.
- Human skin consists of three superimposed tissues: the epidermis, the outermost, the dermis, and the hypodermis, the deepest.
- the natural human epidermis is composed mainly of three types of cells, which are the keratinocytes, a very large majority, melanocytes and Langerhans cells. Each of these cell types contributes by its own functions to the essential role played in the body by the skin.
- the dermis provides the epidermis with a solid support. It is also its nourishing element because it contains a vascularization whose epidermis is free. It consists mainly of fibroblasts and an extracellular matrix itself composed of various extracellular proteins including among others collagen fibers, elastin and various glycoproteins.
- the hypodermis which is invaginated in the dermis and is attached to the overlying dermis by collagen and elastin fibers, consists essentially of a type of cell specialized in the accumulation and storage of fats, adipocytes. It is the energy reservoir of the body.
- Adipocytes are mature cells resulting from a process of differentiation of fibroblasts into pre-adipocytes and adipocytes; this process is called adipogenesis and / or adipocyte differentiation.
- the roundness and / or overweight are related to the dysfunction of these adipocytes, which contain varying amounts of stored fat in the form of triglycerides.
- These triglycerides are synthesized in vivo by the adipocytes themselves, according to enzymatic type reactions (lipogenesis), from the free fatty acids contained in the blood in the form of lipoproteins (via a lipoprotein lipase) and glucose brought in particular by the intermediate of certain foods (via an acetyl-CoA carboxylase).
- the triglycerides thus formed, then stored, in the cells of adipocytes can also degrade (lipolysis), always under the action of enzymes.
- the active agents to fight against the thickening of the hypodermis which are molecules of synthetic or natural origin, have biological mechanisms. Indeed, these molecules target mature adipocytes, by intervening on the metabolism of fatty acids which is one of the privileged targets in the control of this adipocyte lipid overload. This metabolism can be modulated:
- triglyceride lipase or hormone-sensitive lipase
- stimulating cyclic AMP generally by activation of adenylcyclase, or by causing its accumulation by inhibition of phosphodiesterase.
- Other biological pathways have been explored to influence the mechanism of lipogenesis and / or lipolysis. It has thus been proposed to use antagonists of neuropeptide Y (NPY) receptors, which is a neuromediator involved in a number of physiological processes and whose involvement in the regulation of lipolysis has been demonstrated (P. Valet J. Clin Invest, 1990, 85, 291-295). It is also possible to use ⁇ 2 -receptor antagonists or ⁇ -adrenergic receptor agonists. Cytosoluble control can also be used, using activators of the production of interleukin 11 (IL11), by cutaneous epidermal cells and / or cells of the sebaceous gland.
- IL11 interleukin 11
- All these active ingredients are usually formulated in creams or gels, in which other constituents (other active ingredients or excipients) are present.
- topical lotions may leave marks that may stain worn clothing after applying the formulation or leave a sticky skin feeling.
- additives having emission and / or absorption properties in the infrared region also interact with the skin.
- These additives may be shaped into polymeric compositions, in particular based on polyamide, which are then spun to constitute so-called "active" fibers that can be used, for example, to design textile articles making it possible to reduce cellulite.
- active fibers that can be used, for example, to design textile articles making it possible to reduce cellulite.
- the operation of these textile articles is physical / thermal, that is to say that there is a thermoregulation on the surface of the skin through which the microcirculation is activated, and which promotes the elimination cellulite.
- the glue has no isolated action on improving cellulite, it is only an aid to maintaining the cosmetic formulation on the skin;
- the patch helps maintain and accelerates the absorption of the cosmetic active
- bioceramic coated bermuda and cosmetic cream containing bioceramics have the same mechanism of action and no additional effects related to the use of both products are observed;
- the fabric has a function of supporting the active substance, which is generally released due to the friction tissue / skin.
- One of the aims of the present invention is therefore to propose a new product that is more efficient and does not have the disadvantages mentioned above.
- the invention meets this need by proposing a cosmetic kit to significantly improve the appearance of the skin, including the roughness and the firmness of the skin which are altered due to the presence of cellulite.
- the invention relates to a cosmetic kit comprising:
- a topical formulation comprising at least one cosmetic active agent and
- the present invention also relates to the cosmetic use of the kit of the invention to improve the appearance of the skin, in particular to prevent and / or fight against cellulite or orange peel and / or to refine the silhouette.
- the cosmetic use according to the invention makes it possible to increase the elasticity and firmness of the skin, the intensification of collagen synthesis, the increase in blood microcirculation and the improvement of thermoregulation of the skin. skin.
- the kit of the invention implements a topical formulation comprising at least one cosmetic active.
- the cosmetic active ingredient according to the invention is advantageously an active agent having a cellulite reduction effect.
- cellulite reduction effect in the context of the invention means a compound whose activity leads to reducing the thickness of the hypodermis and / or preventing its thickening, in particular by controlling the renewal and / or the number of adipocytes, via inhibition and / or a decrease in the transformation of fibroblasts into pre-adipocytes and adipocytes.
- the topical formulation of the invention may be in the form of an aqueous, alcoholic or aqueous-alcoholic solution or suspension or of an oily suspension or of a solution or dispersion of the lotion or serum type, an emulsion of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (oil in water) or conversely (water in oil), or a triple (water in oil in water or oil in water) in Oil), or a suspension or emulsion of soft, semi-solid or solid consistency of the cream, gel, microemulsion or ionic and / or nonionic type vesicular dispersions.
- These formulations are prepared according to the usual methods.
- This formulation can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a mousse . It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick.
- the formulation according to the invention will be in the form of a lotion, a serum, a milk, a cream, an oil, a stick, a patch or even a spray or aerosol.
- the proportion of the fatty phase may range from 2 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the formulation.
- the oils, the waxes, the emulsifiers and the coemulsifiers used in the formulation in emulsion form are chosen from those conventionally used in the cosmetics field.
- the emulsifier and the coemulsifier are present, in the formulation, in a proportion ranging from 0.1 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the formulation.
- the emulsion may further contain lipid vesicles.
- the fatty phase may represent more than 90% of the total weight of the formulation.
- the formulation of the invention may also contain the usual adjuvants in the cosmetic fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, chelating agents, odor absorbers and dyestuffs.
- adjuvants in the cosmetic fields such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, chelating agents, odor absorbers and dyestuffs.
- these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01% to 20% of the total weight of the formulation.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and / or into the nanoparticles.
- mineral oils vasline oil
- vegetable oils liquid fraction of shea butter, sunflower oil
- animal oils perhydrosqualene
- synthetic oils Purcellin oil
- silicone oils or waxes cyclomethicone
- fluorinated oils perfluoropolyethers
- bees carnauba or paraffin waxes.
- fatty alcohols and fatty acids stearic acid
- emulsifiers that may be used in the invention, mention may be made, for example, of glycerol stearate, polysorbate 60 and the PEG-6 / PEG-32 / glycol stearate mixture sold under the name Tefose® 63 by the company Gattefosse.
- hydrophilic gelling agents that may be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, ethylcellulose and polyethylene.
- carboxyvinyl polymers carboxyvinyl polymers
- acrylic copolymers such as acrylate / alkylacrylate copolymers
- polyacrylamides polysaccharides
- polysaccharides such as hydroxypropylcellulose
- natural gums and clays and, as lipophilic gelling agents
- modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica,
- anti-lipogenesis agents interleukin-11 activators.
- xanthine derivatives such as caffeine and its derivatives, in particular the 1-hydroxyalkylxanthines described in document FR-A-2, 617,401, caffeine citrate, theophylline and its derivatives, theobromine, acefylline, aminophylline, the chloroethylthéophylline, diprofylline, diniprophylline, etamiphylline and its derivatives, etofylline, proxyphylline;
- xanthine derivatives such as the combination of caffeine and silanol (methylsilanetriol caffeine derivative), and for example the product marketed by the company Exsymol under the name caféisilane C;
- compounds of natural origin containing xanthine bases and in particular caffeine, such as extracts of tea, coffee, guarana, mate, cola (Cola Nitida) and in particular the dry extract of guarana fruit ( Paulina sorbilis) containing 8 to 10% caffeine;
- extracts of cangzhu extracts of chrysanthellum indicum, extracts of dioscorea rich in diosgenin or diosgenin or pure hecogenin and their derivatives,
- Extracts of Coleus such as C. Forskohlii, C. blumei, C. esquirolii, C. scutellaroides, C. xanthantus and C. Barbatus, such as Coleus Barbatus root extract containing 60% forskolin,
- Extract of marine origin extracts of algae or phytopancton, such as rhodysterol or Laminaria Digitata extract marketed under the name PHYCOX75 by the company Secma, the skeletonema algae described in patent FR 2
- the peptides or proteins are preferably chosen from:
- protamines and their derivatives such as those described in document FR-A-2, 758,724.
- active agents acting on microcirculation mention may be made of flavonoids, ruscogenins, natural or synthetic esculosides (including Permethol marketed by the SOCHIBO company), escin extracted from horse chestnuts, nicotinates, heparin methyl chalcone, holly, lavender or rosemary essential oils, extracts of Ammi visnaga.
- the cosmetic active agent is chosen from phosphodiesterase inhibitors, active agents acting on microcirculation (vasoprotectants or vasodilators), firming and / or anti-glycating agents (preventing the binding of sugar to the collagen fibers) and / or anti-oxidants, anti-lipogenesis agents, and mixtures thereof.
- the amount of cosmetic asset can vary to a large extent and depends on the nature of the asset or assets used.
- the cosmetic active agent (s) are present in a concentration ranging from 0.0001% to 20%, preferably from 0.001% to 10% and even more preferentially from 0.1% to 5% by weight relative to the total weight of the formulation.
- the topical formulations according to the invention contain at least two cosmetic active agents.
- the cosmetic active can be either (i) encapsulated in a coating such as microspheres, nanospheres, oleosomes or nanocapsules, or (ii) compartmentalized in a fatty phase containing the main constituents of sebum.
- the formulation may be in a form such that the active agent is encapsulated in the core or the wall of a coating such as microspheres, nanospheres, oleosomes, niosomes or nanocapsules, preferably nanocapsules.
- nanoparticles are able to cross the superficial layers of the stratum corneum and / or the follicular ostium and penetrate into the upper layers of the living epidermis to release the active ingredient. This penetration into deeper layers widens the action space of active ingredients and protects them from rapid elimination by simple friction.
- 'nanoparticles' mainly encompasses two different systems: 'nanospheres' consisting of a polymer matrix in which the active ingredient is absorbed and / or adsorbed and / or mixed, as well as 'nanocapsules' having a core-like structure envelope, that is to say a structure consisting of a liquid lipid core at room temperature formed or containing the active ingredient in solubilized form or pure, which heart is encapsulated in a continuous protective envelope insoluble in the medium.
- the nanocapsules according to the present invention are generally small in order to obtain optimal bioavailability of the active compound.
- the size of these nanocapsules is between 10 nm and 1000 nm and more particularly between 30 nm and 500 nm.
- nanocapsules can be used according to the present invention.
- Nanocapsules made of biodegradable polymers penetrate the skin and degrade in the epidermis under the action of the enzymes that are present, whereas the nanocapsules in non-biodegradable polymers only penetrate the superficial layers of the stratum corneum and are eliminated naturally during renewal of the skin.
- microspheres of natural or synthetic polymers or fats with a melting point greater than 50 ° C. loaded with at least one active product, and of which at least 80% by weight of these microspheres have a diameter of between 3 ⁇ m and 1 ⁇ m described in application EP 0 375 520; vehicles consisting of porous particles of size between 10 .mu.m and 100 .mu.m to release, in a controlled manner, the active ingredients described in US Pat. No. 4,690,825.
- the kit of the invention implements a textile article constituted at least in part by polymer fibers which have a capacity for transmitting and / or absorbing infrared radiation in the wavelength range between 2 m and 20 m. pm.
- the polymer fibers according to the invention preferably have a number of infrared radiation absorption peaks greater than 10 in the following ten frequency ranges: 3.00 +/- 0.30 ⁇ , 6.20 +/- 0, 50 ⁇ , 8.00 +/- 0.25 ⁇ , 8.50 +/- 0.25 ⁇ , 9.00 +/- 0.25m, 9.50 +/- 0.25 ⁇ , 10.00 +/- 0 , 25 ⁇ , 10.50 +/- 0.25 ⁇ , 11.00 +/- 0.25 ⁇ , 14.60 +/- 2.10 ⁇ , at least one peak being present in at least 7 of these ten frequency ranges.
- the infrared radiation absorption spectrum may be determined by any method known to those skilled in the art. One possible method is the use of a Bruker Equinox 55 device, with a resolution of 4 cm -1, in which case the spectrum obtained is in ATR ("Atenuated Total Reflectance") form, using a ZnSe crystal.
- the polymer may be selected from the group consisting of polyesters, polyolefins, cellulose-ester-based polymers such as cellulose acetate, cellulose propionate, rayon, viscose and polymers of the same family. acrylic polymers and copolymers, polyamides, polyhexamethylene adipamide (PA66) or polycaproamide (PA6), or copolymers thereof in all proportions, or mixtures of any of the polymers mentioned above.
- polyesters polyolefins
- cellulose-ester-based polymers such as cellulose acetate, cellulose propionate, rayon, viscose and polymers of the same family.
- acrylic polymers and copolymers polyamides, polyhexamethylene adipamide (PA66) or polycaproamide (PA6), or copolymers thereof in all proportions, or mixtures of any of the polymers mentioned above.
- the polymer which composes the fiber is based on polyamide, chosen between polyamide 6, polyamide 66 and copolymers of polyamide 6 / polyamide 66 in all proportions.
- the polymer fibers according to the invention comprise in the polymer matrix, mineral fillers having absorption and / or emission properties in the far-infrared region 2-20 ⁇ m.
- the mineral fillers are chosen from oxides, sulphates, carbonates, phosphates and silicates.
- the oxide is selected from titanium dioxide, silicon dioxide and magnesium oxide.
- the sulphate may be selected from alkali metal sulphates, preferably from barium sulphate, calcium sulphate and strontium sulphate.
- the carbonate is advantageously chosen from calcium carbonate or sodium carbonate.
- the silicate is chosen from aluminosilicates, preferably from actinolite, tourmaline, serpentine and kaolin.
- the phosphate may be chosen from zirconium phosphates, apatite or their mixtures.
- the mineral fillers are of at least one type chosen from oxides, sulphates, carbonates, phosphates and silicates.
- the mineral fillers are of two types chosen from the following types: oxides, sulphates, carbonates, phosphates and silicates.
- the mineral fillers are of three types chosen from among the following types: oxides, sulphates, and silicates.
- the fiber comprises three mineral fillers.
- at least two mineral fillers selected from titanium dioxide, barium sulfate, and tourmaline are present in the fiber.
- the combination of the three mineral fillers is preferably the combination of titanium dioxide / alkali metal sulphate / alumino-silicate; preferably titanium dioxide / barium sulfate / tourmaline.
- the proportion by weight of the three mineral fillers is between 80:10:10 and 10:30:60, and more specifically in proportions of 50:25:25.
- the proportion by weight of the combination of mineral fillers relative to the total weight of the polymeric composition is greater than 1.0%, preferably greater than or equal to 1.5% or more. preferably still greater than or equal to 2.5%.
- the proportion by weight of the combination of inorganic fillers relative to the total weight of the polymeric composition is less than 9%, preferably less than 6%, advantageously less than 4.5%.
- the mineral fillers according to the invention advantageously have an average particle size of less than 2 m.
- the mineral fillers of the polymeric composition advantageously have a particle size of less than 1.0 ⁇ m, preferably a particle size of less than 0.5 ⁇ .
- the mineral fillers are incorporated during the synthesis phase of the polymer, or by direct mixing with the polymer during the spinning phase of the filaments, or by means of a concentrate of particles in the form of a masterbatch. ), which can be subsequently diluted to predetermined concentrations in the polymeric mass during the spinning phase.
- the process for obtaining such fibers according to the invention may consist in producing a suspension of the mineral fillers such as, for example, an aluminosilicate, titanium dioxide and an alkali metal sulphate stabilized with surfactants.
- the suspension is then added to the synthesis of the polyamide.
- An alternative is to introduce a part of the mineral fillers, previously put in the form of a masterbatch in the molten polymer at the time of spinning.
- the polyamide obtained is cooled, cut and remelted before passing through an extruder to form the fiber.
- the polyamide fibers according to the invention contain the mineral fillers uniformly dispersed in the polymer matrix.
- the mineral fillers can be introduced into the molten polymer by means of a mixing device, for example upstream of a spinning device.
- a mixing device for example upstream of a spinning device.
- fiber is the set of yarns, fibers and filaments that can be obtained by spinning.
- the fibers obtained from the polymeric compositions presented in the present invention can be subjected to all the textile treatments known to those skilled in the art, such as extrusion, stretching, texturing, dyeing, finishing etc.
- the polymer fibers used in the textile article are fibers marketed under the names "infra-red emitter son” or “FIR emitter yarns” or EMANA ® by RHODIA.
- These are polyamide 66 fibers comprising three mineral fillers: titanium dioxide, an acali metal sulfate, and an alumino-silicate.
- the textile articles can be obtained from a single type of fiber, or from a mixture of fibers of different types.
- textile articles is meant in particular fabrics, knits and nonwovens.
- the textile articles are made by known techniques using polyamide fibers as raw material.
- the interaction between the textile article and the skin creates a thermoregulation and promotes blood microcirculation.
- Such stimulation results in a decrease in cellulite.
- the textile article is in the form of a garment, preferably a Bermuda shorts, a tights, pants or any other textile article in direct contact with the skin.
- a textile article as defined above in combination with the topical formulation comprising a cosmetic active agent allows better absorption and transport of the active ingredients of the topical formulation, also resulting in better elimination of the compounds targeted by the cosmetic actives.
- the invention therefore also relates to the cosmetic use of the cosmetic kit as defined above to improve the appearance of the skin, in particular to prevent and / or fight against cellulite or orange peel and / or to refine the skin. silhouette, especially by increasing the elasticity and firmness of the skin.
- the topical formulation and the textile article are used successively.
- the use of the cosmetic kit comprises the topical application to the skin of the topical formulation comprising at least one cosmetic active agent followed by the application, on the area of the skin where the topical formulation has been applied, of the textile article constituted at least in part by polymer fibers which have a capacity of emission and / or absorption of infrared radiation in the wavelength range between 2 ⁇ and 20 ⁇ .
- the application of the textile article having a capacity for emitting and / or absorbing infrared radiation in the wavelength range between 2 ⁇ and 20 ⁇ consists in wearing the textile article, in particular under the shape of a garment, for example a bermuda, a tights or pants.
- the kit according to the invention can be used locally on the areas of the body marked by a thickening of the hypodermis.
- the topical formulation comprising at least one cosmetic active on the areas of the body to be refined, in particular on the hips, buttocks, thighs, abdomen and abdominal belt, will be applied.
- a garment made at least partly from polymer fibers which have a capacity of emission and / or absorption of infrared radiation in the wavelength range between 2 ⁇ and 20 ⁇ .
- the wearing of the recommended garment is preferably a minimum of 6 hours per day.
- the application of the topical formulation followed by the wearing of the textile article will be carried out daily, for example once or twice a day, for a duration of treatment of several weeks, generally from 10 days to 8 weeks, preferably from 2 to 8 weeks.
- the wearing of the garment should be made a few minutes after the application of the topical formulation, as soon as the skin has a dry touch.
- the treatment can be renewed periodically, depending on the thickness and / or thickening of the hypodermis and / or cellulite and / or orange peel. the individual to treat.
- the cosmetic use according to the invention also makes it possible to increase the elasticity and firmness of the skin, the intensification of collagen synthesis, the increase in blood microcirculation and the improvement of thermoregulation of the skin. .
- the combination of the topical formulation and the textile article makes it possible to obtain greater efficiency in the reduction of cellulite.
- the transmitting / absorbing article of infrared radiation amplifies the effect of the topical formula, in particular by thermoregulation of the skin and thus improves the absorption of the cosmetic active ingredients,
- the transmitting / absorbing infrared radiation textile article promotes the transport and permeability of the topical formulation by increasing the blood microcirculation of the treated area;
- FIG. 1 represents a diagram of a graph of the measurement of mechanical deformation of the skin as a function of time according to the cutometry method.
- FIG. 1 shows the measurement of this deformation (S) during aspiration, which leads to the determination of the following parameters:
- Topical formulation A gel comprising 1.5% by weight of caffeine, 0.3% by weight of salicylic acid and 0.3% by weight of retinol.
- Topical formulation B emulsion comprising 2.0% by weight of caffeine, 0.3% by weight of Ginko-Biloba and 0.3% by weight of retinol.
- Topical formulation C emulsion 1.5% by weight of caffeine, 0.3% by weight of salicylic acid and 0.3% by weight of thorny hedge (Ruscus aculeatus).
- Topical formulation D (commercial formulation ROC - RETINOL® Anti-Cellulite): retinol, caffeine, forskolin; TetraHydroxylPropyl Ethylenediamine (THPE) and Carnitine.
- Topical formulation (commercial formulation BIOTHERM® - Celluli Laser®): complex of fibrins, plankton, caffeine, ginseng, Ginkgo Biloba, kola nuts.
- Topical formulation F (commercial formulation VICHY® - Lipocure Serum®): water, alcohol, cyclohexasiloxane, propylene glycol, glycerine, caffeine, dimethicone phosphate peg-7, triethanolamine, caprylic / capric peg-6, lycerides, carbomer, manganese gluconate , salicylic acid, escin, ginkgo biloba, rutinyl disodium disulfate, dioscorea opposita, xanthan gum, acrylate / C10-30 alkyl acrylate crosspolymer.
- VICHY® - Lipocure Serum® water, alcohol, cyclohexasiloxane, propylene glycol, glycerine, caffeine, dimethicone phosphate peg-7, triethanolamine, caprylic / capric peg-6, lycerides, carbomer, manganese gluconate , salicylic acid,
- Topical Formulation F (L'Oreal® Commercial Formulation - Perfect Slim Lifting Pro®): water, alcohol, propylene glycol, glycerine, caffeine, dimethicone salicylic acid, silica, mint extract, ginkgo-biloba, extract of Ruscus aculeatus, perfume, extract of "wild Yan", limonene, linalool.
- Topical formulation H (Procter & Gamble® commercial formulation - PLAY®): water, glycerin, niacinamide, isohexadecane, dimethicone, isopropyl isostearate, polyacrylamide, sorbitan estearate, cetyl ethanol, sucrose polycottonseedate, tocopheryl acetate, C13-14 isoparaffin , panthenol, benzyl alcohol, titanium dioxide, stearyl ethanol, dimethiconol, ethylparaben, PEG-100 stearate, perfume, laureth-7, propylparaben, stearic acid, disodium EDTA, sodium ascorbyl phosphate, bht, zinc oxide, citric acid, extract of camellia sinensis leaf, methylparaben, c 19140, ammonium polyacrylate, c 16035.
- the reduction in skin roughness was measured using a standardized method of analyzing the skin surface with a 3D Nikon D70S 3D photographic camera. Captured images are analyzed by specialized software (Scion for Windows Software) which translates the relief into roughness. Roughness is the measure of the average variation (standard deviation) of the peaks and valleys of the image. Standard treatments against cellulite based on topical formulations (topical formulations A to G) alone or using only a textile article emitting / absorbing in the wavelength range 2-20 ⁇ , show a reduction in the roughness of the skin from 8 to 12%.
- the increase in skin firmness was also measured with a standardized method which consists of analyzing cutometry: that is to say of the measurement of the mechanical deformation curve of the skin according to FIG.
- the principle of this technique is to create on the surface of the skin a depression and to measure the induced vertical displacement of the skin.
- This technique is based on a suction method. A depression is created in the probe in order to suck the skin.
- the cutometer measures the vertical displacement of the surface of the skin as a function of time and the depression exerted in the probe. We can thus determine the rigidity of the skin and its ability to recover its initial state.
- the value "F” was measured at time zero ("F 0 ”) and after 30 days (“F 30 ”) using tissue h) for 8 hours.
- composition of the invention which comprises both the topical formulation comprising at least one cosmetic active and the Rhodia technology of infra-red emitting son, for the treatment of the appearance of orange peel and reduction of the appearance of cellularite.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112013012295A BR112013012295A2 (pt) | 2010-11-23 | 2011-11-18 | "kit cosmético e usos cosméticos do kit" |
EP11794852.1A EP2642969A1 (fr) | 2010-11-23 | 2011-11-18 | Kit cosmetique et utilisation pour ameliorer l'aspect de la peau |
US13/989,386 US20130316024A1 (en) | 2010-11-23 | 2011-11-18 | Cosmetic kit and use for improving the appearance of the skin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR1059654 | 2010-11-23 | ||
FR1059654A FR2967573B1 (fr) | 2010-11-23 | 2010-11-23 | Kit cosmetique et utilisation pour ameliorer l'aspect de la peau |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012069902A1 true WO2012069902A1 (fr) | 2012-05-31 |
Family
ID=44310782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/002746 WO2012069902A1 (fr) | 2010-11-23 | 2011-11-18 | Kit cosmetique et utilisation pour ameliorer l'aspect de la peau |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130316024A1 (fr) |
EP (1) | EP2642969A1 (fr) |
BR (1) | BR112013012295A2 (fr) |
FR (1) | FR2967573B1 (fr) |
WO (1) | WO2012069902A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2676662A1 (fr) * | 2012-06-18 | 2013-12-25 | Rhodia Poliamida E Especialidades Ltda | Composition polymérique contenant des charges minérales, pour améliorer la cicatrisation de la peau |
US9814798B2 (en) | 2011-05-18 | 2017-11-14 | Rhodia Poliamida E Especialidades Ltda | Yarns, fibers or filaments, textile article, and medical device obtained from said yarns for skin cicatrization |
EP3031431B1 (fr) | 2014-12-11 | 2018-09-19 | Skin'up | Article textile massant |
EP4368168A1 (fr) * | 2022-11-11 | 2024-05-15 | Ringoldas Voityla | Composition pour traitements anticellulite |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2999613B1 (fr) * | 2012-12-19 | 2016-12-30 | Sophie Beauge-Duguet | Materiau textile impregne de principes actifs et comprenant des particules de ceramique |
WO2016091316A1 (fr) | 2014-12-11 | 2016-06-16 | Skin'up | Article textile massant |
ES2773604A1 (es) * | 2019-01-11 | 2020-07-13 | Bionox Group Spain S L | Material textil con microparticulas bioceramicas que emite en el infrarrojo lejano en cuatro longitudes de onda concretas simultaneamente |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690825A (en) | 1985-10-04 | 1987-09-01 | Advanced Polymer Systems, Inc. | Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen |
EP0274961A1 (fr) | 1986-12-31 | 1988-07-20 | Centre National De La Recherche Scientifique (Cnrs) | Procédé de préparation de systèmes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
FR2617401A1 (fr) | 1987-06-30 | 1989-01-06 | Oreal | Composition cosmetique a action-cellulitique et amincissante dont le principe actif est une 1-hydroxyalkyxanthine |
EP0375520A1 (fr) | 1988-12-20 | 1990-06-27 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Composition cosmétique ou pharmaceutique contenant des microsphères de polymères ou de corps gras chargées d'au moins un produit actif |
FR2659554A1 (fr) | 1990-03-16 | 1991-09-20 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
WO1993005753A1 (fr) | 1991-09-13 | 1993-04-01 | L'oreal | Composition pour un traitement cosmetique et/ou pharmaceutique de longue duree des couches superieures de l'epiderme par une application topique sur la peau |
EP0780115A1 (fr) | 1995-12-21 | 1997-06-25 | L'oreal | Nanoparticules enrobées d'une phase lamellaire à base de tensioactif siliconé et compositions les contenant |
EP0838217A2 (fr) | 1996-10-23 | 1998-04-29 | Sanofi | Composition cosmétique contenant un antagoniste des récepteurs du neuropeptide Y |
FR2758724A1 (fr) | 1997-01-24 | 1998-07-31 | Javenech | Composition topique a base de protamine pour le traitement de la cellulite et des surcharges ponderales |
FR2774292A1 (fr) | 1998-02-05 | 1999-08-06 | Inovat Sarl | Compositions pharmaceutiques, cosmetiques et/ou alimentaires a base de diatomees |
FR2781231A1 (fr) | 1998-07-17 | 2000-01-21 | Sederma Sa | Compositions cosmetiques amincissantes |
FR2782921A1 (fr) | 1998-09-09 | 2000-03-10 | Dior Christian Parfums | Extrait lipidique de l'algue skeletonema, procede de preparation et utilisation dans des domaines cosmetique et pharmaceutique, notamment dermatologique |
FR2786693A1 (fr) | 1998-12-04 | 2000-06-09 | Dior Christian Parfums | Agent cosmetique pour obtenir une action amincissante |
FR2787730A1 (fr) | 1998-12-29 | 2000-06-30 | Oreal | Nanocapsules a base de poly(alkylene adipate), leur procede de preparation et compositions cosmetiques ou dermatologiques les contenant |
FR2788058A1 (fr) | 1998-12-30 | 2000-07-07 | Sederma Sa | Compositions cosmetiques amincissantes |
EP1025901A1 (fr) | 1998-12-29 | 2000-08-09 | L'oreal | Nanocapsules à base de polymères anioniques hydrodispersibles, leur procédé de préparation et compositions cosmétiques ou dermatologiques les contenant |
EP1034839A1 (fr) | 1999-03-02 | 2000-09-13 | L'oreal | Nanocapsules à base de polymères dendritiques |
WO2002087700A1 (fr) * | 2001-04-26 | 2002-11-07 | The Procter & Gamble Company | Methode, necessaire et dispositif de traitement cosmetique d'etats cutanes |
EP1961408A2 (fr) * | 2007-02-26 | 2008-08-27 | Beiersdorf Aktiengesellschaft | Produit de combinaison cosmétique destiné à l'amélioration de l'aspect optique extérieur |
WO2009077834A2 (fr) | 2007-12-14 | 2009-06-25 | Rhodia Poliamida E Especialidades Ltda | Composition polymérique, procédé pour la fabrication de la composition polymérique, articles à base de cette composition polymérique et utilisation de ces articles |
FR2934496A1 (fr) * | 2008-07-30 | 2010-02-05 | Rhodia Poliamida E Especialidades Ltda | Utilisation d'articles a base d'une composition polymerique pour stimuler la peau |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002506801A (ja) * | 1998-03-16 | 2002-03-05 | ザ、プロクター、エンド、ギャンブル、カンパニー | 哺乳類の皮膚のセルライトを軽減する方法 |
-
2010
- 2010-11-23 FR FR1059654A patent/FR2967573B1/fr active Active
-
2011
- 2011-11-18 WO PCT/IB2011/002746 patent/WO2012069902A1/fr active Application Filing
- 2011-11-18 BR BR112013012295A patent/BR112013012295A2/pt not_active Application Discontinuation
- 2011-11-18 EP EP11794852.1A patent/EP2642969A1/fr not_active Withdrawn
- 2011-11-18 US US13/989,386 patent/US20130316024A1/en not_active Abandoned
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690825A (en) | 1985-10-04 | 1987-09-01 | Advanced Polymer Systems, Inc. | Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen |
EP0274961A1 (fr) | 1986-12-31 | 1988-07-20 | Centre National De La Recherche Scientifique (Cnrs) | Procédé de préparation de systèmes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
FR2617401A1 (fr) | 1987-06-30 | 1989-01-06 | Oreal | Composition cosmetique a action-cellulitique et amincissante dont le principe actif est une 1-hydroxyalkyxanthine |
EP0375520A1 (fr) | 1988-12-20 | 1990-06-27 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Composition cosmétique ou pharmaceutique contenant des microsphères de polymères ou de corps gras chargées d'au moins un produit actif |
FR2659554A1 (fr) | 1990-03-16 | 1991-09-20 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
WO1993005753A1 (fr) | 1991-09-13 | 1993-04-01 | L'oreal | Composition pour un traitement cosmetique et/ou pharmaceutique de longue duree des couches superieures de l'epiderme par une application topique sur la peau |
EP0780115A1 (fr) | 1995-12-21 | 1997-06-25 | L'oreal | Nanoparticules enrobées d'une phase lamellaire à base de tensioactif siliconé et compositions les contenant |
EP0838217A2 (fr) | 1996-10-23 | 1998-04-29 | Sanofi | Composition cosmétique contenant un antagoniste des récepteurs du neuropeptide Y |
FR2758724A1 (fr) | 1997-01-24 | 1998-07-31 | Javenech | Composition topique a base de protamine pour le traitement de la cellulite et des surcharges ponderales |
FR2774292A1 (fr) | 1998-02-05 | 1999-08-06 | Inovat Sarl | Compositions pharmaceutiques, cosmetiques et/ou alimentaires a base de diatomees |
FR2781231A1 (fr) | 1998-07-17 | 2000-01-21 | Sederma Sa | Compositions cosmetiques amincissantes |
FR2782921A1 (fr) | 1998-09-09 | 2000-03-10 | Dior Christian Parfums | Extrait lipidique de l'algue skeletonema, procede de preparation et utilisation dans des domaines cosmetique et pharmaceutique, notamment dermatologique |
FR2786693A1 (fr) | 1998-12-04 | 2000-06-09 | Dior Christian Parfums | Agent cosmetique pour obtenir une action amincissante |
FR2787730A1 (fr) | 1998-12-29 | 2000-06-30 | Oreal | Nanocapsules a base de poly(alkylene adipate), leur procede de preparation et compositions cosmetiques ou dermatologiques les contenant |
EP1025901A1 (fr) | 1998-12-29 | 2000-08-09 | L'oreal | Nanocapsules à base de polymères anioniques hydrodispersibles, leur procédé de préparation et compositions cosmétiques ou dermatologiques les contenant |
FR2788058A1 (fr) | 1998-12-30 | 2000-07-07 | Sederma Sa | Compositions cosmetiques amincissantes |
EP1034839A1 (fr) | 1999-03-02 | 2000-09-13 | L'oreal | Nanocapsules à base de polymères dendritiques |
WO2002087700A1 (fr) * | 2001-04-26 | 2002-11-07 | The Procter & Gamble Company | Methode, necessaire et dispositif de traitement cosmetique d'etats cutanes |
EP1961408A2 (fr) * | 2007-02-26 | 2008-08-27 | Beiersdorf Aktiengesellschaft | Produit de combinaison cosmétique destiné à l'amélioration de l'aspect optique extérieur |
WO2009077834A2 (fr) | 2007-12-14 | 2009-06-25 | Rhodia Poliamida E Especialidades Ltda | Composition polymérique, procédé pour la fabrication de la composition polymérique, articles à base de cette composition polymérique et utilisation de ces articles |
FR2934496A1 (fr) * | 2008-07-30 | 2010-02-05 | Rhodia Poliamida E Especialidades Ltda | Utilisation d'articles a base d'une composition polymerique pour stimuler la peau |
Non-Patent Citations (1)
Title |
---|
P. VALET, J. CLIN. INVEST., vol. 85, 1990, pages 291 - 295 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9814798B2 (en) | 2011-05-18 | 2017-11-14 | Rhodia Poliamida E Especialidades Ltda | Yarns, fibers or filaments, textile article, and medical device obtained from said yarns for skin cicatrization |
EP2676662A1 (fr) * | 2012-06-18 | 2013-12-25 | Rhodia Poliamida E Especialidades Ltda | Composition polymérique contenant des charges minérales, pour améliorer la cicatrisation de la peau |
EP3031431B1 (fr) | 2014-12-11 | 2018-09-19 | Skin'up | Article textile massant |
EP4368168A1 (fr) * | 2022-11-11 | 2024-05-15 | Ringoldas Voityla | Composition pour traitements anticellulite |
Also Published As
Publication number | Publication date |
---|---|
FR2967573B1 (fr) | 2012-11-09 |
US20130316024A1 (en) | 2013-11-28 |
FR2967573A1 (fr) | 2012-05-25 |
EP2642969A1 (fr) | 2013-10-02 |
BR112013012295A2 (pt) | 2016-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012069902A1 (fr) | Kit cosmetique et utilisation pour ameliorer l'aspect de la peau | |
CA2749750C (fr) | Compositions de soin de la peau et leurs procedes d'utilisation | |
EP2335683B1 (fr) | Kit de formulation d'un produit cosmétique | |
US20160235661A1 (en) | Cosmetic and topical compositions comprising cannabigerol | |
EP2978503B1 (fr) | Utilisation cosmetique d'un extrait de polygonum bistorta | |
EP0946138B1 (fr) | Utilisation d'un extrait de potentilla erecta dans le domaine de la cosmetique et de la pharmacie | |
FR2809005A1 (fr) | Utilisation du manganese dans le traitement des rides | |
WO2005094776A1 (fr) | Compositions cosmetiques ou dermatologiques et leurs applications | |
EP1676606B1 (fr) | Composition amincissante comprenant une base xanthique, un diméthicone copolyol et une poudre de polyuréthane | |
FR2907338A1 (fr) | Utilisation de l'acide ferulique dans le domaine cosmetique et/ou pharmaceutique | |
FR2862533A1 (fr) | Utilisation cosmetique d'au moins un activateur de la production d'une interleukine 11, comme agent amincissant topique | |
EP2291173B1 (fr) | Association d'extraits de passiflore et d'anchuse utilisable en cosmetique | |
FR3051369A1 (fr) | Extraits de faine de hetre, compositions et utilisations | |
WO2006045932A2 (fr) | Nouvelle utilisation d'huile de chaulmoogra et de guggulipides en therapeutique et en cosmetique. | |
WO2007135268A2 (fr) | Utilisation de peptides en tant que principes actifs amincissants | |
WO2008009813A2 (fr) | Utilisation d'un extrait de gleditsia en cosmétique et en dermatologie | |
EP3043873A1 (fr) | Utilisation cosmetique ou dermatologique d'un extrait de tapirira guyanensis | |
FR2876909A1 (fr) | Composition a base d'huile de chaulmoogra et de bases xanthiques pour le traitement des surchages adipeuses. | |
FR3030275A1 (fr) | Utilisation d'un extrait de lythrum salicaria | |
FR3019988A1 (fr) | Utilisation cosmetique d'un extrait de chicorium intybus | |
FR2876912A1 (fr) | Nouvelle utilisation de guggulipides en therapeutique et en cosmetique | |
FR2992561A1 (fr) | Composition topique apaisante a base d'extraits de paeonia et de nymphaea | |
FR2931358A1 (fr) | Composition comprenant un hydrolysat de proteines de riz et deux derives de vitamine c | |
FR2973695A1 (fr) | Composition a base de cafeine et de triacanthine pour le traitement des surcharges adipeuses. | |
FR2913198A1 (fr) | Utilisation cosmetique d'une association de biotine et de vitamine cg. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11794852 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011794852 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13989386 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013012295 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013012295 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130517 |